Multiple sclerosis, the prototype of demyelinating disease in man, is a relapsing-remitting or progressively disabling disease of unknown cause. The first pathological descriptions of the disease ...

UC Riverside study may lead to new treatments for multiple sclerosis. Multiple sclerosis (MS) affects an estimated 2.3 ...

Multiple sclerosis (MS) is a chronic inflammatory disorder that is thought to impact about 2.3 million people around the ...

Multiple sclerosis (MS) ... the neuronal connections in the central nervous system ... Myelin insulation as a risk factor for axonal degeneration in autoimmune demyelinating disease.

In multiple sclerosis (MS), an alteration of neuronal metabolism caused by dysfunction of its proteasome, the cellular machinery responsible for recycling proteins, contributes to neurodegeneration in ...

Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have inflammation in the cerebellum, the part of the brain that helps control movement ...

Reference: Atkinson KC, Desfor S, Feri M, et al. Decreased mitochondrial activity in the demyelinating cerebellum of progressive multiple sclerosis and chronic EAE contributes to Purkinje cell loss.

Researchers identify enzymes ceramide synthase 5 and 6 as key players in how saturated fats worsen multiple sclerosis symptoms. Study: Neuroprotective effect of neuron-specific deletion of the C16 ...

SAN DIEGO — Data from an open-label extension of VISIONARY-MS support an association between gold nanocrystals and neuronal repair and remyelination in patients with stable multiple sclerosis ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French ...

Motor neurons are cells in your brain and spinal cord that help you walk, talk, and eat. Learn how damage to these cells could affect your movement and what your doctor can do to treat it.